Margetuximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Margetuximab
Accession Number
DB14967
Description

Margetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • MGAH22

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Margetuximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Margetuximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Margetuximab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Margetuximab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Margetuximab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Margetuximab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Margetuximab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Margetuximab.
AvelumabThe risk or severity of adverse effects can be increased when Avelumab is combined with Margetuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
K911R84KEW
CAS number
1350624-75-7

References

General References
Not Available
Wikipedia
Margetuximab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentHER2 Positive Breast Cancers / Neoplasms, Metastatic1
2CompletedTreatmentBreast Cancer1
2RecruitingTreatmentBreast Cancer / HER2 Positive Breast Cancers / Stage II Breast Cancer / Stage III Breast Cancer1
2RecruitingTreatmentMetastatic Breast Cancer1
2, 3RecruitingTreatmentGastroesophageal Junction Cancer / HER2 Positive Gastric Cancer / HER2-positive Gastric Cancer / Malignant Neoplasm of Stomach1
1Active Not RecruitingTreatmentBreast Cancer / Malignant Neoplasm of Stomach1
1Not Yet RecruitingTreatmentHER2 Positive Metastatic Breast Cancers1
1RecruitingTreatmentAdvanced Solid Tumors / Diffuse Large B-Cell Lymphoma (DLBCL) / Gastroesophageal Cancer (GC) / HER2 Positive Breast Cancers / HER2 Positive Gastric Cancer / HER2-positive Gastric Cancer / Malignant Neoplasm of Stomach / Neoplasms, Hematologic / Ovarian Cancer1
1, 2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableAvailableNot AvailableHER2 Positive Breast Cancers / HER2-positive Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:38 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates